🔎 Trials Near Me

Home › Rhabdomyosarcoma

Rhabdomyosarcoma clinical trials recruiting in the U.S.

26 studies for Rhabdomyosarcoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

RecruitingPhase 1
Ages 3 to 39 · All sexes · Updated Sep 29, 2026 · NCT06865664

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

Recruiting
All ages · All sexes · Updated Aug 21, 2026 · NCT07514819

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05210374

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07628634

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Recruiting
Up to age 39 · All sexes · Updated Jul 13, 2026 · NCT06796543

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190

Familial Investigations of Childhood Cancer Predisposition

RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

RecruitingPhase 1/2
6 Months – 30 Years · All sexes · Updated Jun 2, 2026 · NCT04796012

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Jan 22, 2026 · NCT04995003

Molecular Analysis Of Solid Tumors

RecruitingObservational study
Up to age 25 · All sexes · Updated Nov 12, 2025 · NCT01050296

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 16, 2025 · NCT02508038

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.